UNSPSC 51313435: Pheniramine aminosalicylate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H20N2.C7H7NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0NA6Q9I2PB, chemically known as benzoic acid, 4-amino-2-hydroxy-, compd. with n,n-dimethyl-.gamma.-phenyl-2-pyridinepropanamine (1:1), but more generally known as pheniramine aminosalicylate, which bears US NIH Compound Identifier 92952.

European Medicines Agency schedules pheniramine aminosalicylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09768MIG. Most nations, for tariff purposes, schedule pheniramine aminosalicylate under HS 29333999. SMILES: CN(C)CCC(C1CCCCC1)C2CCCCN2.C1CC(C(CC1N)O)C(=O)O.

UNSPSC 51313435 Pheniramine aminosalicylate is a Commodity code that, despite its specific pharmaceutical naming, sees state and local procurement activity focused on broader pharmaceutical supply and drug-management products rather than this single active ingredient alone. Recent opportunities tagged to this code reflect state and local governments' purchases of naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals through cooperative purchasing vehicles and direct procurement channels. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances coordinating purchases across member jurisdictions. Work solicited under the code ranges from annual naloxone and drug-disposal-system procurement with quarterly delivery cycles to large-scale generic pharmaceutical supply agreements serving state and local facilities.

Geographically, recent activity appears concentrated in Florida, Texas, and Minnesota, with multistate cooperative purchasing extending into Oregon. Seminole County, Florida issued IFB60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with a July 26, 2023 response deadline, requiring quarterly deliveries to the Seminole County Community Health Building and mandating E-Verify compliance and drug-free workplace certification. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling preliminary groundwork for a future formal RFP. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, with proposals due March 26, 2026, requiring vendors to supply through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certifications.